

Canadian VHL Alliance (CVHLA)

My story

VHL and CVHLA

Future coalition of partners



My daughters

CVHLA Board Members








von Hippel-Lindau

 Von Hippel-Lindau (VHL) is most often a hereditary condition associated with tumors arising in multiple organs.

Areas of the Body Affected by von Hippel-Lindau Disease





CVHLA Background

VHL in Canada:

Approximately 1 in 36,000; 1100 VHLers in Canada

CVHLA

- Organization over 20 years old
- Mission: Research, Education and Support

Research

- \$120k in Cancer Research Society partnership
 - Became \$480k in Canadian Research on VHL



CVHLA Background

Patient Education and Support:

Information: email newsletter, website, social media

Current Fundraising:

Walk, Canada Helps – \$20-30k per year



CVHLA Background

- Nov 2022 International Symposium with VHL Alliance
 - Merck sponsorship

Belzutifan/Welireg

- July 2021 HC Approval HOPE: Belzutifan/Welireg
- Sept. 2023 CADTH, Nov. 2023 INESSS positive rec.
 - CORD, KCC, Bob Bick, PCC, CNET, RQMO
- ? Early 2024: pCPA Price Negotiation
- ? Summer 2024: Provincial Coverage



CVHLA Today

Current Patient Support:

- Volunteer working board of 7 (2 patients, 5 family/friends)
- Scientific and Medical Advisory Council
 - Dr. Maryam Soleimani BC Cancer VHL Clinic
 - Renee Hofstedter, Alexandra Volenik Gen. Coun. UHN
- Information: newsletter, 5 Brochures by U of T: VHL intro, questions, genetics

Cannot do more without professional staff!

Must partner with other Rare Disease organizations!



CVHLA Future Coalition of Partners

Future Patient Support:

Belzutifan Videos (partner with VHLA?)

I-Rare: RQMO/Quebec Coalition of Orphan Disorders, CanPKU+

- 1-800 Number and disease information
- Registries, clinical trials
- Regional Communities



CVHLA Future Coalition of Partners

I-Rare/RQMO/CanPKU+, CORD + CRDN?

- Connections to specialists in each province
- Support
 - Community: BIPOC, Psychosocial,
 - Events, fundraising
 - Mental Health
 - Coordination of appointments etc.
- More information:
 - Screenings, genetic, trials



CVHLA Future Coalition of Partners


Patient Group Support

I-Rare/ RQMO/CanPKU+, CORD + CRDN?

- Structure, processes, Tools
- Education and training:
 - Leadership training
 - Operations, governance, strategy
 - Advocacy (CORD),
 - Fundraising for research and operations
 - Standard Registry consent/privacy
- Partners: Pharma, clinicians, researchers, government



Patient Group Centre of Expertise



Build Bridges from

The Rare Disease Patient Community

to

The Healthcare Ecosystem



Most groups are barely surviving

Vast/complex